Research programme: cannabinoid receptor CB1 antagonists - Prosidion
Latest Information Update: 31 May 2010
At a glance
- Originator Prosidion
- Class Small molecules
- Mechanism of Action Cannabinoid receptor CB1 antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 18 Jan 2006 (OSI) Prosidion is the diabetes and obesity business unit of OSI Pharmaceuticals
- 01 Jun 2005 Preclinical trials in Obesity in United Kingdom (unspecified route)